Cytopia begins Phase II
Thursday, 04 September, 2008
Cytopia [ASX: CYT] has commenced enrolment for its Phase 1b/II study of CYT997 for brain cancer.
CYT997 is a vascular disrupting agent being tested in patients with the aggressive brain cancer glioblastoma multiforme.
Around 30 patients will be involved in the study, which will be conducted at a number of clinical centres in Australia and overseas. CYT997 will be used in combination with two other marketed anticancer agents.
Glioblastomas often resurface even after surgical resection or radiation therapy, but are highly vascular and dependent on their own abnormal blood supply for growth. CYT997 is aimed at disrupting this supply.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
